Oncomine Tumor Mutation Load Assay
Detection of cancer driver variants and assessment of tumor mutational burden (TMB), an emerging immuno-oncology biomarker, with next-generation sequencing
Immune checkpoint inhibitors have changed the treatment paradigm for a variety of cancers, but not all patients will respond to immunotherapies. Relevant biomarkers have shown to be as important as the therapies since they guide in our quest to help match patients with the appropriate treatment.